HCFA Needs to Do More to Prevent Medicare/Medicaid Fraud and Abuse

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

WASHINGTON--Medicare and Medicaid are hard pressed to stay ahead of profiteers bent on cheating the system administered by the Health Care Financing Administration (HCFA).

WASHINGTON--Medicare and Medicaid are hard pressed to stay aheadof profiteers bent on cheating the system administered by theHealth Care Financing Administration (HCFA).

Sarah F. Jaggar, director of health financing and policy issuesfor HCFA, testified before the House Subcommittee on Human Resourcesand Intergovernmental Relations that HCFA's fraud and abuse preventionprograms are weak.

She said that Medicare and Medicaid offer strong incentives forproviders to overprovide services, that HCFA has few controlsto detect questionable billing practices and too few limits onthe types of providers allowed to bill the federal agency, andthat there is little chance that profiteers will be prosecutedor will have to repay fraudulently obtained money.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
Related Content